Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

df6771b0-4b6c-4565-a2f1-4d919f8d68c9

0713111a-b8cc-5927-8ffa-541c58b37f15

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.300
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • DNA_REPAIR+0.200
  • PANCREAS_BETA_CELLS+0.200
  • MYC_TARGETS_V1+0.100
  • NOTCH_SIGNALING+0.100
  • FATTY_ACID_METABOLISM+0.000
  • PROTEIN_SECRETION+0.000
  • SPERMATOGENESIS+0.000

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.600
  • ALLOGRAFT_REJECTION-0.500
  • IL2_STAT5_SIGNALING-0.500
  • IL6_JAK_STAT3_SIGNALING-0.500
  • INFLAMMATORY_RESPONSE-0.500
  • TNFA_SIGNALING_VIA_NFKB-0.500
  • APOPTOSIS-0.400
  • CHOLESTEROL_HOMEOSTASIS-0.400
  • COMPLEMENT-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R16
bladder-landscape@3
0.903
2ERR2208948
melanoma-umap@29
0.891
3TCGA-KU-A66S-01A-21R-A30B-07
head-neck@1
0.887
4GSM5359423
bladder-landscape@3
0.886
5SRR25617882
breast-umap@18
B0.874
6SRR4296068
lung-landscapes@6
cohortA10.869
7SRR5088853
melanoma-umap@29
0.866
8s0095168
melanoma-umap@29
0.865
9SRR1797244
lung-landscapes@6
cohortSC0.863
10s_150324_3a
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.861

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 7 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.400Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
DNA_REPAIR0.200Idelalisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
MYC_TARGETS_V10.100Inavolisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered